According to the Federal Statistical Office<\/a> (Destatis), approximately 106,000 abortions were reported in Germany in 2025. This represents a slight decrease of 0.7 percent compared to the previous year. The figure remains above the level recorded between 2014 and 2020, when annual cases ranged from roughly 99,000 to 101,000. The data does not allow for an assessment of the causes behind this trend, and no information is available on the personal reasons for choosing an abortion under the counseling regulation.<\/p>\nIn 2025, seven out of ten women (69 percent) who underwent an abortion were between the ages of 18 and 34, while 20 percent were aged 35 to 39. Nine percent of the women were 40 years or older, and 3 percent were under 18. Additionally, 44 percent of the women had not given birth to a child before the abortion.<\/p>\n
Ninety-six percent of abortions reported in 2025 were performed under the so-called counseling regulation. Medical reasons or indications due to sexual offenses accounted for 4 percent of cases.<\/p>\n
For the first time in 2025, the medication Mifegyne was the most common abortion method, used in 45 percent of procedures. The vacuum aspiration method, which had been the most frequent until 2024, accounted for 43 percent. Most procedures were performed on an outpatient basis, with about 86 percent taking place in doctors’ offices or surgical centers and 12 percent in hospital outpatient settings.<\/p>\n
The majority of abortions (80 percent) occurred within the first eight weeks of pregnancy, while 3 percent were performed after the 12th week or later.<\/p>\n
Ten-Year Comparison Shows Fewer Abortions in Younger Age Groups<\/p>\n
Compared to 2015, when 99,200 cases were recorded, the number of abortions in 2025 was 6.5 percent (or 6,500 cases) higher. However, trends varied by age group. Declines were observed among women aged 15 to 17 (down 6.1 percent, or 200 cases) and those aged 20 to 24 (down 4.4 percent, or 900 cases). In contrast, significant increases occurred among women aged 30 to 34 (up 8.5 percent, or 1,900 cases), 35 to 39 (up 27.5 percent, or 4,500 cases), and 40 to 44 (up 24.1 percent, or 1,600 cases).<\/p>\n
These developments are partly attributable to demographic shifts. Over the same period, the number of women aged 15 to 17 fell by 4.0 percent, and the number of women aged 20 to 24 declined by 4.9 percent. At the same time, the female population rose by 2.4 percent for those aged 30 to 34, by 14.7 percent for those aged 35 to 39, and by 6.6 percent for those aged 40 to 44.<\/p>\n
When measured as abortions per 10,000 women, rates remained nearly unchanged for women aged 15 to 17 (25 in both years) and for those aged 20 to 24 (rising from 92 to 94). Among women aged 30 to 34, the rate increased from 86 to 92; among those aged 35 to 39, from 67 to 75; and among women aged 40 to 44, from 26 to 31.<\/p>\n
Trend Toward Earlier Abortions and Increased Use of Mifegyne<\/p>\n
In 2025, abortions were more frequently performed in earlier weeks of pregnancy compared to a decade earlier. Forty-nine percent of abortions in 2025 took place within the first six weeks, up from 36 percent in 2015. The share of abortions performed between the seventh and eleventh weeks of pregnancy decreased from 61 percent to 48 percent over the same period.<\/p>\n
The use of the medication Mifegyne for abortions has grown steadily. Its share rose from 19 percent in 2015 to 45 percent in 2025, representing an increase of 28,800 cases. Conversely, the share of vacuum aspiration procedures fell sharply from 64 percent to 43 percent, a decline of 18,700 cases.<\/p>\n
Interactive table based on the Store Companies dataset for this report.<\/p>\n
\t\t\t\tSort: Rank
\n\t\t\t\tSort: Company A-Z
\n\t\t\t\tSort: Headquarters A-Z<\/p>\n
\t\t\t\t\t#
\n\t\t\t\t\tCompany
\n\t\t\t\t\tHeadquarters
\n\t\t\t\t\tFocus
\n\t\t\t\t\tScale
\n\t\t\t\t\tNote<\/p>\n
\t\t\t\t\t\t1
\n\t\t\t\t\t\tBayer AG
\n\t\t\t\t\t\tLeverkusen
\n\t\t\t\t\t\tPharmaceuticals, Corticosteroids
\n\t\t\t\t\t\tGlobal
\n\t\t\t\t\t\tMajor diversified pharma producer<\/p>\n
\t\t\t\t\t\t2
\n\t\t\t\t\t\tMerck KGaA
\n\t\t\t\t\t\tDarmstadt
\n\t\t\t\t\t\tPharmaceuticals, Corticosteroids
\n\t\t\t\t\t\tGlobal
\n\t\t\t\t\t\tIncludes Merck Serono business<\/p>\n
\t\t\t\t\t\t3
\n\t\t\t\t\t\tBoehringer Ingelheim
\n\t\t\t\t\t\tIngelheim am Rhein
\n\t\t\t\t\t\tPharmaceuticals, Corticosteroids
\n\t\t\t\t\t\tGlobal
\n\t\t\t\t\t\tLarge R&D-based pharma company<\/p>\n
\t\t\t\t\t\t4
\n\t\t\t\t\t\tViatris (Mylan) GmbH
\n\t\t\t\t\t\tFrankfurt
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tGlobal
\n\t\t\t\t\t\tPart of Viatris global group<\/p>\n
\t\t\t\t\t\t5
\n\t\t\t\t\t\tSTADA Arzneimittel AG
\n\t\t\t\t\t\tBad Vilbel
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tLarge
\n\t\t\t\t\t\tMajor European generics company<\/p>\n
\t\t\t\t\t\t6
\n\t\t\t\t\t\tHexal AG
\n\t\t\t\t\t\tHolzkirchen
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tLarge
\n\t\t\t\t\t\tPart of Novartis Sandoz division<\/p>\n
\t\t\t\t\t\t7
\n\t\t\t\t\t\tRatiopharm GmbH
\n\t\t\t\t\t\tUlm
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tLarge
\n\t\t\t\t\t\tMajor generics producer, part of Teva<\/p>\n
\t\t\t\t\t\t8
\n\t\t\t\t\t\tAliud Pharma GmbH
\n\t\t\t\t\t\tLaichingen
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tGeneric pharmaceuticals<\/p>\n
\t\t\t\t\t\t9
\n\t\t\t\t\t\tDermapharm AG
\n\t\t\t\t\t\tGr\u00fcnwald
\n\t\t\t\t\t\tSpecialty Pharma, Dermatology
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tFocus on dermatological corticosteroids<\/p>\n
\t\t\t\t\t\t10
\n\t\t\t\t\t\tDr. Gerhard Mann GmbH
\n\t\t\t\t\t\tBerlin
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tPharma-chemicals and generics<\/p>\n
\t\t\t\t\t\t11
\n\t\t\t\t\t\tMibe GmbH Arzneimittel
\n\t\t\t\t\t\tBrehna
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tJenaHexal\/Mibe group<\/p>\n
\t\t\t\t\t\t12
\n\t\t\t\t\t\tTAD Pharma GmbH
\n\t\t\t\t\t\tCuxhaven
\n\t\t\t\t\t\tSterile pharmaceuticals
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tInjectable corticosteroids<\/p>\n
\t\t\t\t\t\t13
\n\t\t\t\t\t\tAbZ-Pharma GmbH
\n\t\t\t\t\t\tUlm
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tGeneric drug manufacturer<\/p>\n
\t\t\t\t\t\t14
\n\t\t\t\t\t\tCT Arzneimittel GmbH
\n\t\t\t\t\t\tBerlin
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tGeneric pharmaceuticals<\/p>\n
\t\t\t\t\t\t15
\n\t\t\t\t\t\tAzupharma GmbH
\n\t\t\t\t\t\tB\u00f6blingen
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tPharmaceutical manufacturing<\/p>\n
\t\t\t\t\t\t16
\n\t\t\t\t\t\tWinthrop Arzneimittel GmbH
\n\t\t\t\t\t\tMunich
\n\t\t\t\t\t\tHospital Pharma, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tPart of Sanofi group<\/p>\n
\t\t\t\t\t\t17
\n\t\t\t\t\t\tG. Pohl-Boskamp GmbH & Co. KG
\n\t\t\t\t\t\tHohenlockstedt
\n\t\t\t\t\t\tPharmaceuticals, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tFamily-owned pharma company<\/p>\n
\t\t\t\t\t\t18
\n\t\t\t\t\t\tMIP Pharma GmbH
\n\t\t\t\t\t\tBlieskastel
\n\t\t\t\t\t\tSterile injectables
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tSpecializes in aseptic filling<\/p>\n
\t\t\t\t\t\t19
\n\t\t\t\t\t\tDermasence GmbH
\n\t\t\t\t\t\tH\u00fcrth
\n\t\t\t\t\t\tDermatology, Corticosteroids
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tDermatological products<\/p>\n
\t\t\t\t\t\t20
\n\t\t\t\t\t\tKlosterfrau Healthcare Group
\n\t\t\t\t\t\tCologne
\n\t\t\t\t\t\tOTC, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tHealthcare and OTC products<\/p>\n
\t\t\t\t\t\t21
\n\t\t\t\t\t\tW\u00f6rwag Pharma GmbH & Co. KG
\n\t\t\t\t\t\tB\u00f6blingen
\n\t\t\t\t\t\tSpecialty Pharma
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tFocus on metabolic & neurological<\/p>\n
\t\t\t\t\t\t22
\n\t\t\t\t\t\tMCM Klosterfrau GmbH
\n\t\t\t\t\t\tCologne
\n\t\t\t\t\t\tOTC, Corticosteroids
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tPart of Klosterfrau Group<\/p>\n
\t\t\t\t\t\t23
\n\t\t\t\t\t\tKade Besins GmbH
\n\t\t\t\t\t\tBerlin
\n\t\t\t\t\t\tPharmaceuticals, Hormones
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tPart of Besins Healthcare<\/p>\n
\t\t\t\t\t\t24
\n\t\t\t\t\t\tGalenica GmbH
\n\t\t\t\t\t\tBerlin
\n\t\t\t\t\t\tGenerics, Corticosteroids
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tGeneric drug company<\/p>\n
\t\t\t\t\t\t25
\n\t\t\t\t\t\tMeyerCousins GmbH
\n\t\t\t\t\t\tFrankfurt
\n\t\t\t\t\t\tSpecialty Pharma
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tPharmaceutical marketing<\/p>\n
\t\t\t\t\t\t26
\n\t\t\t\t\t\tDermasel GmbH
\n\t\t\t\t\t\tWaltrop
\n\t\t\t\t\t\tDermatology, Corticosteroids
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tDermatological therapeutics<\/p>\n
\t\t\t\t\t\t27
\n\t\t\t\t\t\tKrewel Meuselbach GmbH
\n\t\t\t\t\t\tEitorf
\n\t\t\t\t\t\tPhytopharma, OTC
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tAlso produces classic pharmaceuticals<\/p>\n
\t\t\t\t\t\t28
\n\t\t\t\t\t\tPohl-Boskamp GmbH
\n\t\t\t\t\t\tHohenlockstedt
\n\t\t\t\t\t\tPharmaceuticals
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tManufacturer of pharmaceuticals<\/p>\n
\t\t\t\t\t\t29
\n\t\t\t\t\t\tbeta GmbH
\n\t\t\t\t\t\tHannover
\n\t\t\t\t\t\tPharmaceuticals
\n\t\t\t\t\t\tSmall
\n\t\t\t\t\t\tPharmaceutical production<\/p>\n
\t\t\t\t\t\t30
\n\t\t\t\t\t\tDermapharm Vertriebs GmbH
\n\t\t\t\t\t\tGr\u00fcnwald
\n\t\t\t\t\t\tDermatology, Corticosteroids
\n\t\t\t\t\t\tMedium
\n\t\t\t\t\t\tSales arm of Dermapharm Group<\/p>\n
This report provides a comprehensive view of the medicaments containing corticosteroid hormones industry in Germany, tracking demand, supply, and trade flows across the national value chain. It explains how demand across key channels and end-use segments shapes consumption patterns, while also mapping the role of input availability, production efficiency, and regulatory standards on supply.<\/p>\n
Beyond headline metrics, the study benchmarks prices, margins, and trade routes so you can see where value is created and how it moves between domestic suppliers and international partners. The analysis is designed to support strategic planning, market entry, portfolio prioritization, and risk management in the medicaments containing corticosteroid hormones landscape in Germany.<\/p>\n
Quick navigation
\nKey findings<\/p>\n
Domestic demand is shaped by both household and industrial usage, with trade flows linking local supply to imports and exports.
\n Pricing dynamics reflect unit values, freight costs, exchange rates, and regulatory shifts that affect sourcing decisions.
\n Supply depends on input availability and production efficiency, creating a distinct national cost curve.
\n Market concentration varies by segment, creating different competitive landscapes and entry barriers.
\n The 2035 outlook highlights where capacity investment and demand growth are most aligned within the country.
\nReport scope<\/p>\n
The report combines market sizing with trade intelligence and price analytics for Germany. It covers both historical performance and the forward outlook to 2035, allowing you to compare cycles, structural shifts, and policy impacts.<\/p>\n
Market size and growth in value and volume terms
\n Consumption structure by end-use segments
\n Production capacity, output, and cost dynamics
\n Trade flows, exporters, importers, and balances
\n Price benchmarks, unit values, and margin signals
\n Competitive context and market entry conditions
\nProduct coverageProdcom 21201270 – Medicaments containing corticosteroid hormones, their derivatives and structural analogues, put up in measured doses or for retail saleCountry coverageCountry profile and benchmarks<\/p>\n
This report provides a consistent view of market size, trade balance, prices, and per-capita indicators for Germany. The profile highlights demand structure and trade position, enabling benchmarking against regional and global peers.<\/p>\n
Methodology<\/p>\n
The analysis is built on a multi-source framework that combines official statistics, trade records, company disclosures, and expert validation. Data are standardized, reconciled, and cross-checked to ensure consistency across time series.<\/p>\n
International trade data (exports, imports, and mirror statistics)
\n National production and consumption statistics
\n Company-level information from financial filings and public releases
\n Price series and unit value benchmarks
\n Analyst review, outlier checks, and time-series validation<\/p>\n
All data are normalized to a common product definition and mapped to a consistent set of codes. This ensures that comparisons across time are aligned and actionable.<\/p>\n
Forecasts to 2035<\/p>\n
The forecast horizon extends to 2035 and is based on a structured model that links medicaments containing corticosteroid hormones demand and supply to macroeconomic indicators, trade patterns, and sector-specific drivers. The model captures both cyclical and structural factors and reflects known policy and technology shifts in Germany.<\/p>\n
Historical baseline: 2012-2025
\n Forecast horizon: 2026-2035
\n Scenario-based sensitivity to income growth, substitution, and regulation
\n Capacity and investment outlook for major producing companies<\/p>\n
Each projection is built from national historical patterns and the broader regional context, allowing the report to show where growth is concentrated and where risks are elevated.<\/p>\n
Price analysis and trade dynamics<\/p>\n
Prices are analyzed in detail, including export and import unit values, regional spreads, and changes in trade costs. The report highlights how seasonality, freight rates, exchange rates, and supply disruptions influence pricing and margins.<\/p>\n
Price benchmarks by country and sub-region
\n Export and import unit value trends
\n Seasonality and calendar effects in trade flows
\n Price outlook to 2035 under baseline assumptions
\nProfiles of market participants<\/p>\n
Key producers, exporters, and distributors are profiled with a focus on their operational scale, geographic footprint, product mix, and market positioning. This helps identify competitive pressure points, partnership opportunities, and routes to differentiation.<\/p>\n
Business focus and production capabilities
\n Geographic reach and distribution networks
\n Cost structure and pricing strategy indicators
\n Compliance, certification, and sustainability context
\nHow to use this report<\/p>\n
Quantify domestic demand and identify the most attractive segments
\n Evaluate export opportunities and prioritize target destinations
\n Track price dynamics and protect margins
\n Benchmark performance against leading competitors
\n Build evidence-based forecasts for investment decisions<\/p>\n
This report is designed for manufacturers, distributors, importers, wholesalers, investors, and advisors who need a clear, data-driven picture of medicaments containing corticosteroid hormones dynamics in Germany.<\/p>\n
FAQ
\nWhat is included in the medicaments containing corticosteroid hormones market in Germany?<\/p>\n
The market size aggregates consumption and trade data, presented in both value and volume terms.<\/p>\n
How are the forecasts to 2035 built?<\/p>\n
The projections combine historical trends with macroeconomic indicators, trade dynamics, and sector-specific drivers.<\/p>\n
Does the report cover prices and margins?<\/p>\n
Yes, it includes export and import unit values, regional spreads, and a pricing outlook to 2035.<\/p>\n
Which benchmarks are included?<\/p>\n
The report benchmarks market size, trade balance, prices, and per-capita indicators for Germany.<\/p>\n
Can this report support market entry decisions?<\/p>\n
Yes, it highlights demand hotspots, trade routes, pricing trends, and competitive context.<\/p>\n
\t\t\t\t\t\t1. INTRODUCTION<\/p>\n
Report Scope and Analytical Framing<\/p>\n
Report DescriptionResearch Methodology and the Analytical FrameworkData-Driven Decisions for Your BusinessGlossary and Product-Specific Terms2. EXECUTIVE SUMMARY<\/p>\n
Concise View of Market Direction<\/p>\n
Key FindingsMarket TrendsStrategic ImplicationsKey Risks and Watchpoints3. DOMESTIC MARKET SIZE AND DEVELOPMENT PATH<\/p>\n
Market Size, Growth and Scenario Framing<\/p>\n
Market Size: Historical Data (2012-2025) and Forecast (2026-2035)Growth Outlook and Market Development Path to 2035Growth Driver DecompositionScenario Framework and Sensitivities4. CATEGORY SCOPE, DEFINITIONS AND BOUNDARIES<\/p>\n
Commercial and Technical Scope<\/p>\n
What Is Included and How the Market Is DefinedMarket Inclusion CriteriaProduct \/ Category DefinitionExclusions and BoundariesDistinction From Adjacent Products and Substitute Categories5. CATEGORY STRUCTURE, SEGMENTATION AND PRODUCT MATRIX<\/p>\n
How the Market Splits Into Decision-Relevant Buckets<\/p>\n
By Product Type \/ ConfigurationBy Application \/ End UseBy Customer \/ Buyer TypeBy Channel \/ Business Model \/ Technology PlatformSegment Attractiveness MatrixProduct Matrix and Segment Growth Logic6. DOMESTIC DEMAND, CUSTOMER AND BUYER ARCHITECTURE<\/p>\n
Where Demand Comes From and How It Behaves<\/p>\n
Consumption \/ Demand: Historical Data (2012-2025) and Forecast (2026-2035)Demand by End-Use and Buyer GroupDemand by Customer \/ Consumer SegmentPurchase Criteria, Switching Logic and Adoption BarriersReplacement, Replenishment and Installed-Base DynamicsFuture Demand Outlook7. DOMESTIC PRODUCTION, SUPPLY AND VALUE CHAIN<\/p>\n
Supply Footprint and Value Capture<\/p>\n
Production in the CountryDomestic Manufacturing FootprintCapacity, Bottlenecks and Supply RisksValue Chain Logic and Margin PoolsDistribution and Route-to-Market Structure8. IMPORTS, EXPORTS AND SOURCING STRUCTURE<\/p>\n
Trade Flows and External Dependence<\/p>\n
ExportsImportsTrade BalanceImport DependenceSourcing Risks and Resilience9. PRICING, PROMOTION AND COMMERCIAL MODEL<\/p>\n
Price Formation and Revenue Logic<\/p>\n
Domestic Price Levels and CorridorsPricing by Segment \/ Specification \/ ChannelCost Drivers and Margin LogicPromotion, Discounting and Procurement PatternsRevenue Quality and Commercial Levers10. COMPETITIVE LANDSCAPE AND PORTFOLIO POWER<\/p>\n
Who Wins and Why<\/p>\n
Market Structure and ConcentrationCompetitive ArchetypesSegment-by-Segment Competitive IntensityPortfolio Breadth and Product PositioningCapability MatrixStrategic Moves, Partnerships and Expansion Signals11. DOMESTIC MARKET STRUCTURE AND CHANNEL LOGIC<\/p>\n
How the Domestic Market Works<\/p>\n
Core Demand CentersLocal Production and Distribution RolesChannel StructureBuyer and Procurement ArchitectureRegional Imbalances Within the Country12. GROWTH PLAYBOOK AND MARKET ENTRY<\/p>\n
Commercial Entry and Scaling Priorities<\/p>\n
Where to PlayHow to WinDistributor \/ Partner \/ Direct Entry OptionsCapability ThresholdsEntry Risks and Mitigation13. WHERE TO PLAY NEXT: MOST ATTRACTIVE GROWTH OPPORTUNITIES<\/p>\n
Where the Best Expansion Logic Sits<\/p>\n
Most Attractive Product NichesMost Attractive Customer SegmentsWhite Spaces and Unsaturated OpportunitiesHigh-Margin and Underpenetrated PocketsMost Promising Product Adjacencies14. PROFILES OF MAJOR COMPANIES<\/p>\n
Leading Players and Strategic Archetypes<\/p>\n
Leading Manufacturers and SuppliersProduction Footprint and CapacitiesProduct Portfolio and Segment FocusPricing Positioning and Indicative Price LogicChannel \/ Distribution StrengthStrategic Archetypes15. METHODOLOGY, SOURCES AND DISCLAIMER<\/p>\n
How the Report Was Built<\/p>\n
Modeling LogicSource RegisterPublications, Regulatory and Industry ReferencesAnalytical NotesDisclaimer\t\t\t\t\t<\/p>\n
Loading News content from Store report…<\/p>\n
\t\t\t\t\t\t\t\t\t\t\t\t\tBayer AG<\/p>\n
Major diversified pharma producer<\/p>\n
Merck KGaA<\/p>\n
Includes Merck Serono business<\/p>\n
Boehringer Ingelheim<\/p>\n
Large R&D-based pharma company<\/p>\n
Viatris (Mylan) GmbH<\/p>\n
Part of Viatris global group<\/p>\n
STADA Arzneimittel AG<\/p>\n
Major European generics company<\/p>\n
Hexal AG<\/p>\n
Part of Novartis Sandoz division<\/p>\n
Ratiopharm GmbH<\/p>\n
Major generics producer, part of Teva<\/p>\n
Aliud Pharma GmbH<\/p>\n
Generic pharmaceuticals<\/p>\n
Dermapharm AG<\/p>\n
Focus on dermatological corticosteroids<\/p>\n
Dr. Gerhard Mann GmbH<\/p>\n
Pharma-chemicals and generics<\/p>\n
Mibe GmbH Arzneimittel<\/p>\n
JenaHexal\/Mibe group<\/p>\n
TAD Pharma GmbH<\/p>\n
Injectable corticosteroids<\/p>\n
AbZ-Pharma GmbH<\/p>\n
Generic drug manufacturer<\/p>\n
CT Arzneimittel GmbH<\/p>\n
Generic pharmaceuticals<\/p>\n
Azupharma GmbH<\/p>\n
Pharmaceutical manufacturing<\/p>\n
Winthrop Arzneimittel GmbH<\/p>\n
Part of Sanofi group<\/p>\n
G. Pohl-Boskamp GmbH & Co. KG<\/p>\n
Family-owned pharma company<\/p>\n
MIP Pharma GmbH<\/p>\n
Specializes in aseptic filling<\/p>\n
Dermasence GmbH<\/p>\n
Dermatological products<\/p>\n
Klosterfrau Healthcare Group<\/p>\n
Healthcare and OTC products<\/p>\n
W\u00f6rwag Pharma GmbH & Co. KG<\/p>\n
Focus on metabolic & neurological<\/p>\n
MCM Klosterfrau GmbH<\/p>\n
Part of Klosterfrau Group<\/p>\n
Kade Besins GmbH<\/p>\n
Part of Besins Healthcare<\/p>\n
Galenica GmbH<\/p>\n
Generic drug company<\/p>\n
MeyerCousins GmbH<\/p>\n
Pharmaceutical marketing<\/p>\n
Dermasel GmbH<\/p>\n
Dermatological therapeutics<\/p>\n
Krewel Meuselbach GmbH<\/p>\n
Also produces classic pharmaceuticals<\/p>\n
Pohl-Boskamp GmbH<\/p>\n
Manufacturer of pharmaceuticals<\/p>\n
beta GmbH<\/p>\n
Pharmaceutical production<\/p>\n
Dermapharm Vertriebs GmbH<\/p>\n
Sales arm of Dermapharm Group<\/p>\n
Loading Reviews content from Store report…<\/p>\n
Loading Dashboard content from Store report…<\/p>\n
Loading Macro Indicators content from Store report…<\/p>\n","protected":false},"excerpt":{"rendered":"Apr 29, 2026 According to the Federal Statistical Office (Destatis), approximately 106,000 abortions were reported in Germany in…\n","protected":false},"author":2,"featured_media":8424,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[8252,8255,8251,8256,8258,3402,5,8250,8257,8253,8254],"class_list":{"0":"post-8423","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-germany","8":"tag-abortion-demographics","9":"tag-abortion-methods","10":"tag-abortion-statistics","11":"tag-abortion-trends","12":"tag-counseling-regulation","13":"tag-destatis","14":"tag-germany","15":"tag-germany-abortions-2025","16":"tag-germany-federal-statistical-office","17":"tag-mifegyne","18":"tag-vacuum-aspiration"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/8423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/comments?post=8423"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/8423\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media\/8424"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media?parent=8423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/categories?post=8423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/tags?post=8423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}